Stocks across multiple sectors swung sharply in midday trading after a wave of corporate updates, including earnings beats, guidance moves, major partnership announcements, and a high-stakes patent ruling affecting two biotech names. Among the biggest movers, Accenture surged after reporting fiscal fourth-quarter results that topped expectations, while Liquidia dropped steeply following a court decision related to a lung treatment patent.
Key takeaways
- Accenture jumped after fiscal fourth-quarter revenue and earnings beat guidance and analyst expectations.
- Liquidia tumbled as a federal court ruled on a patent infringement case involving a treatment held by United Therapeutics.
- Constellation Energy climbed on a long-term agreement with Amazon tied to expanding nuclear generation capacity.
- Synopsys surged after an investor day laid out financial targets and included a strategic partnership with OpenAI.
- Several other names moved on guidance, deal news, or acquisition-related developments.
What drove the biggest moves
Accenture shares rose strongly after the professional services firm reported fiscal fourth-quarter results that exceeded its own guidance range and surpassed consensus expectations. Revenue came in above the company’s outlook, and per-share earnings also beat analyst estimates, reinforcing demand resilience in its services business.
McCormick fell even though its third-quarter results beat expectations. The company reported adjusted earnings and revenue ahead of what analysts surveyed by FactSet had forecast, but the stock declined as the market weighed uncertainty tied to its acquisition by Unilever, which also slipped.
McKesson gained after reaffirming fiscal 2027 earnings per share guidance. The company also extended its partnership with CVS Health to support distribution of pharmaceuticals across mail order, specialty, and retail pharmacies as well as distribution centers through June 2032. With investors focused on multi-year earnings visibility, the guidance reiteration helped offset the absence of a new earnings release in the session.
United Therapeutics and Liquidia moved in opposite directions following a Delaware federal court ruling finding that Liquidia’s lung treatment infringed a patent held by United Therapeutics. BTIG upgraded United Therapeutics to buy, arguing that a “large legal win” could clear the way for growth through 2027, while it downgraded Liquidia to neutral and said the decision is expected to restrict Liquidia’s ability to market its treatment. United Therapeutics rose while Liquidia sold off sharply.
Deals, partnerships, and strategy updates
Constellation Energy climbed after announcing a 20-year deal with Amazon supporting expansion of generating capacity at a Maryland nuclear power plant. For investors, the agreement signals long-term demand underpinning nuclear capacity plans, a key factor for companies positioned to monetize steady baseload generation amid ongoing energy transition debates.
Synopsys rallied after hosting an investor day that detailed its growth strategy and long-term financial targets. The company also announced a strategic partnership with OpenAI. Synopsys projected 2027 year-over-year revenue growth of 15% to a range of $11.1 billion to $11.2 billion, which topped what analysts expected for the year according to FactSet. The combination of clearer long-term targets and a prominent technology partnership helped drive the upside momentum.
BJ’s Restaurants advanced after Mizuho upgraded the stock to outperform and raised its price target. The bank cited stronger checks that pushed its third-quarter same-store sales growth estimate above consensus, while expecting upward estimate revisions through 2027.
Vicor surged after raising its third-quarter revenue growth guidance to more than 30% from prior guidance of at least 20%. The update was linked to higher royalties driven by its earlier non-exclusive license with Vertical Power Delivery, highlighting how licensing and customer adoption can translate quickly into near-term expectations.
Corteva dropped after announcing the formal spinoff of its Vylor seed and genetic business, a move the company completed following an appeals court decision that denied a temporary restraining order and preliminary injunction sought to delay the separation. The spinoff left Corteva as a pure-play crop protection company, but the market reaction reflected the adjustments investors typically make when a business is removed from consolidated results.
Other earnings, guidance, and operational updates
Sigma Lithium slid after temporarily suspending mining and industrial production following a 15-day delay in an appeals process in Brazil reviewing the company’s legal defense. The operational pause added near-term uncertainty, and the market response reflected the sensitivity of resource development firms to regulatory and legal timelines.
Acuity Brands fell after forward guidance related to its Acuity Intelligent Spaces business came in slightly below Wall Street expectations, according to StreetAccount. With the lighting and building management equipment company signaling low- to mid-teens net sales growth, investors focused on the gap versus consensus.
Liquidia was also impacted by the court ruling that restricted its commercial outlook tied to marketing the infringing treatment, while McCormick faced acquisition-related overhang despite earnings strength.
Additional mover: The session also included reports of near-term timing and guidance sensitivity across several names, underscoring how investors are prioritizing revenue trajectories, visibility into earnings, and legal or deal-driven event risk.
Bigger picture: what investors are watching
The midday moves reinforced a market pattern in which investors reward companies offering clearer earnings visibility—such as guidance reaffirmations and investor-day targets—while penalizing uncertainty tied to legal outcomes, deal mechanics, or regulatory delays. With earnings season still in motion across multiple sectors, the balance between growth signals (partnerships, capacity agreements, revenue guidance) and event risk (patent litigation, acquisition timelines, operational pauses) continues to drive sharp stock dispersion.
Next for investors, attention will likely shift toward upcoming earnings reports, including scheduled second-quarter results from McKesson on Nov. 4, as well as additional corporate updates and the broader macro calendar that can influence rate expectations and equity valuations.
